Cel-Sci (CVM +6.9%) CEO Geert Kersten drops heavy hints that the firm's Multikine treatment for...


Cel-Sci (CVM +6.9%) CEO Geert Kersten drops heavy hints that the firm's Multikine treatment for head and neck cancer is performing well in Phase 3 trials. "Based on everything that we've seen in the clinic so far, if we continue to see the same results, we will have the first non-toxic cancer therapy," Kersten tells eHealth Radio.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs